Article Correctness Is Author's Responsibility: Oxtellar XR Gains Monotherapy Indication for Partial-Onset Seizures

The article below may contain offensive and/or incorrect content.

The FDA has approved the supplemental New Drug Application for Oxtellar XR to include monotherapy use for the treatment of partial-onset seizures patients aged ?6 years.